Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
The money raised through the Offer for Sale goes to existing investors, not the company.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Hexagon Nutrition Limited, incorporated in 1993 and headquartered in Mumbai, is a research-led nutrition company that develops and manufactures a broad range of nutrition products. Its portfolio spans micronutrient premixes supplied to food and beverage manufacturers, branded wellness and clinical nutrition, therapeutic formulations, and ready-to-use foods used in public health and humanitarian programmes. The company positions itself as an integrated player able to take a product from research and formulation through to manufacturing and marketing. Manufacturing is carried out across four facilities, three in India at Nasik (Maharashtra), Chennai (Tamil Nadu) and Thoothukudi (Tamil Nadu), and one international unit at Tashkent in Uzbekistan. The company runs two research and development centres at Nasik and Chennai staffed by a team of specialists working on formulation science, ingredient interactions and sensory evaluation. As of March 2026 it employed a workforce of over five hundred people. Hexagon sells through a domestic network of more than three hundred and fifty distributors and exports to buyers in over seventy countries across Asia, Africa, Europe and South America. In-house consumer and clinical brands include PENTASURE, OBESIGO and PEDIAGOLD. The business combines a business-to-business premix operation that serves large packaged-food companies with a growing branded wellness and clinical-nutrition franchise, and it supplies micronutrient powders to global public health initiatives.
Hexagon Nutrition raised about 41.66 crore rupees from anchor investors on June 4, 2026, allotting 92,57,696 shares at 45 rupees each. The anchor book was led by Bandhan Small Cap Fund (28.82 percent), with Ampersand Growth Opportunities Fund Scheme I (24.00 percent), CP Capital Limited (23.16 percent), Visionary Value Fund (12.01 percent) and Innovative Vision Fund (12.01 percent) making up the rest.
Source: RHP • Analysis provided for informational purposes
Last Updated: 8 July 2026, 10:30 PM
Integrated nutrition platform
The company operates end to end across research, formulation, manufacturing and marketing, offering everything from micronutrient premixes to clinical and therapeutic nutrition under one roof.
In-house brand portfolio
Proprietary brands such as PENTASURE, OBESIGO and PEDIAGOLD give it a presence in specialised consumer and clinical nutrition alongside its business-to-business premix work.
Research and development depth
Two dedicated R&D centres at Nasik and Chennai focus on formulation science and product development, supporting a differentiated and research-oriented product range.
Global reach in public health nutrition
A supplier of micronutrient powders to international public health programmes, with exports spanning more than seventy countries across several continents.
Regulatory action at the Nasik facility
Reconstruction of part of the Nasik plant following past regulatory action could cause temporary interruptions to production.
Product quality and liability exposure
Sale of expired, defective or non-compliant products could lead to legal claims, recalls and reputational harm.
Raw material dependence without long-term contracts
The business relies on continuous availability of raw materials but does not have binding long-term supply agreements, leaving it exposed to price and availability swings.
Hexagon Nutrition Limited
404 Global Chamber, Adarsh Nagar Link Road, Andheri (W), Mumbai, Maharashtra - 400053
View on Maps →No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.
Customer and segment concentration
A meaningful share of revenue comes from the premix segment and from a limited set of large customers, so the loss of key accounts could weigh on performance.